Greg Yap

Building frontier artificial intelligence to predict and reprogram the interactions between biochemical molecules.

Aurora Therapeutics is reinventing how personalized gene-editing medicines are developed and approved for patients with rare diseases. The company combines state-of-the-art CRISPR engineering with umbrella regulatory pathways and modular CMC frameworks that allow many mutation-specific therapies to move forward in parallel. Aurora’s approach addresses the fundamental economic and operational barriers that have historically prevented treatments for rare mutations, enabling CRISPR therapies to reach patients at population scale. For more information, visit http://auroratherapeutics.com.

Xaira Therapeutics is an integrated biotechnology company driving advances in artificial intelligence to learn the language of life and transform how we treat disease. The company seeks to rethink the drug discovery and development process from end-to-end by bringing together leading talent across three core areas: machine learning research to better understand biology, expansive data generation to power new models, and robust therapeutic product development to treat disease. Xaira is headquartered in the San Francisco Bay Area.

We believe that kids shouldn’t just aspire to get out of bed and drag themselves to class. They should be able to experience joy. They deserve to envision and build a life they’re excited to live. Cartwheel is the trusted mental health partner to schools. We deliver rapid access to care for students and help schools build stronger mental health programs that catch kids before they fall.

Vilya is a cutting-edge computational biotechnology company, co-founded a team of scientists from from the Institute of Protein Design (IPD) led by David Baker, Ph.D. and by ARCH Venture Partners. At Vilya, we are creating a novel class of medicines to precisely target disease biology. Our platform is built on ground-breaking research in advanced computational approaches and taps into uncharted chemical space within cyclic peptides to design new molecular structures not found in nature. We aim to boldly leverage cutting edge computing to change how we design new medicines, and to ultimately cure diseases. Who will love working with us? We are a group of machine learning scientists, computational chemists, medicinal chemists, biologists and scientific enthusiasts that are driven to design and create life-altering medicines that will make a big impact on the world. Learn more about our job openings and join us! join@vilyatx.com

Koala has all the medications and health products your pet needs. We package them by date and time to make pet care simpler. The best part? There are no service or shipping fees — you only pay for what your pet needs.

Evidence-based, accessible, and judgment-free approach to opioid use disorder—right in the privacy of your own home.

Scribe is enabling the creation of genetic medicines through its CRISPR by Design™ approach to genetic modification.

Particle Health: engineered by engineers for engineers Particle is shaping the new standard for healthcare data exchange with a user-friendly API platform. We create intuitive experiences for developers, build scalable infrastructure product teams love, and collaborate with innovative leaders launching data driven healthcare solutions Our mission is to enable simple and secure access to actionable healthcare data for digital health innovators. Unofficially? We also intend to #destroythefaxmachine

At H1, our mission is nothing short of creating a healthier future worldwide by unlocking and democratizing global access to critical expertise, HCP information, claims data, ground-breaking research and discoveries, and connected insights for all – doctors, researchers, industry and, ultimately, patients – bringing everyone closer together to advance medicine and clinical outcomes. Insights derived from H1’s solutions help life sciences and other healthcare organizations accelerate the development, launch, and dissemination of life-saving treatments, drive meaningful engagements with key opinion leaders, and help ensure equitable access to healthcare services.

Genesis Therapeutics – headquartered in Burlingame, CA, with a fully integrated laboratory in San Diego – is unifying AI and biotechnology to discover novel and breakthrough treatments for patients with severe and devastating conditions. We are using a proprietary state-of-the-art generative and predictive AI platform called GEMS (Genesis Exploration of Molecular Space), to accelerate and optimize small molecule drug discovery. The GEMS platform integrates deep learning-based predictive models, molecular simulations, and molecular generative AI. GEMS accelerates hit ID through lead optimization and candidate selection by generating promising molecules for synthesis and experimental testing, and iterating this process through multiple cycles of AI-enabled discovery and optimization. We have leveraged GEMS to build an internal pipeline with multiple programs against high-value targets, including data-poor and canonically undruggable targets where GEMS is uniquely advantaged. In addition, Genesis has two AI platform collaborations across a range of therapeutic areas: Eli Lilly (signed in 2022) and Genentech (signed in 2020). Genesis has raised over $280M in funding from top technology and biotech investors, including Andreessen Horowitz, Rock Springs Capital, T. Rowe Price, Fidelity, Radical Ventures, NVentures (NVIDIAs VC arm), BlackRock, and Menlo Ventures. We are rapidly growing our team with a variety of openings on our machine learning, computational chemistry, and software teams (primarily located in the Bay Area) and our chemistry, biology, and clinical teams (primarily located in San Diego). To learn more about Genesis Therapeutics, or current employment opportunities, please visit our website.

Clear Labs harnesses the power of next-generation sequencing (NGS) to simplify complex diagnostics for clinical and applied markets. By creating a fully automated platform that brings together DNA sequencing, robotics and cloud-based analytics, Clear Labs democratizes genomics applications to deliver increased clarity. Clear Labs’ turnkey platform accelerates outcomes and improves accuracy - from food-borne pathogens to infectious diseases, including SARS CoV-2. With a novel approach, Clear Labs is helping the world better understand, track and mitigate tomorrow’s novel pathogens.

DELFI uses AI, machine learning and whole genome sequencing to sensitively detect unique patterns of DNA fragmentation in the blood of patients with cancer.

Riva Health will use mobile technology and AI to drastically improve hypertension management.

Vital Labs is the first mobile "digital therapeutics" platform for the cardiology industry. Heart disease is the #1 killer in the world. By using mobile devices, patient-provided data, and predictive analytics our platform helps clinicians deliver personalized therapies to patients, which leads to significant reductions in cost while increasing the number of lives saved. The platform was built by PhDs from MIT and UCSF in collaboration with industry leaders in cardiology and healthcare transformation from UCSF, Cincinnati Children’s Hospital, and beyond.

Building frontier artificial intelligence to predict and reprogram the interactions between biochemical molecules.

Aurora Therapeutics is reinventing how personalized gene-editing medicines are developed and approved for patients with rare diseases. The company combines state-of-the-art CRISPR engineering with umbrella regulatory pathways and modular CMC frameworks that allow many mutation-specific therapies to move forward in parallel. Aurora’s approach addresses the fundamental economic and operational barriers that have historically prevented treatments for rare mutations, enabling CRISPR therapies to reach patients at population scale. For more information, visit http://auroratherapeutics.com.

Xaira Therapeutics is an integrated biotechnology company driving advances in artificial intelligence to learn the language of life and transform how we treat disease. The company seeks to rethink the drug discovery and development process from end-to-end by bringing together leading talent across three core areas: machine learning research to better understand biology, expansive data generation to power new models, and robust therapeutic product development to treat disease. Xaira is headquartered in the San Francisco Bay Area.

We believe that kids shouldn’t just aspire to get out of bed and drag themselves to class. They should be able to experience joy. They deserve to envision and build a life they’re excited to live. Cartwheel is the trusted mental health partner to schools. We deliver rapid access to care for students and help schools build stronger mental health programs that catch kids before they fall.